Cantor Fitzgerald started coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a research note published on ...
A research team has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their findings could open new pathways for ...
Researchers uncover new insights into the molecular mechanisms of ADAR1, a protein that regulates RNA-induced immune ...
Interesting Engineering on MSN6d
Scientists unravel RNA-editing mystery, paving way for next-gen cancer treatmentsScientists have made a major discovery about ADAR1—a protein that controls RNA-induced immune responses—paving ...
Welch Foundation, Cancer Prevention and Research Institute of Texas, NIH/National Institutes of Health ...
A research team led by Rice University's Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ...
Newly discovered ADAR1 inhibitor exhibits antitumor effects in prostate cancer March 7, 2025 Novel therapeutic targets for treating the disease remain an unmet need.
HCC, distinct from most cancer types, is neither a hypo- nor a hyper-editing cancer; instead, HCC displays a severely disrupted A to I RNA editing balance induced by the differentially expressed ADARs ...
The planned PIPE is led by Cormorant and also includes investors like ADAR1 Capital Management, BC Capital and Wellington Management. The transaction proceeds will be used to fund BridgeBio ...
That financing will be led by Cormorant Asset Management and will see the likes of Novo Holdings, ADAR1 Capital Management, Omega Funds and BioCapital Advisors, to name a few, scooping up the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback